Sanofi-Aventis S.A. ADR (SNY)

$41.33 -0.27 (-0.65%)
Market Cap 101.29B
Revenue (ttm) 52.85B
Net Income (ttm) 8.84B
EPS (ttm) N/A
PE Ratio 9.23
Forward PE 8.52
Profit Margin 16.72%
Debt to Equity Ratio 0.25
Volume 7,776,911
Avg Vol 3,002,420
Day's Range N/A - N/A
Shares Out 2.42B
Stochastic %K 19%
Beta 0.34
Analysts Sell
Price Target $55.01

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscienti...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande ArmEe, Paris, France
Latest News on SNY
MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval

2026-06-23T10:32:25.000Z - 1 day ago

MacroGenics To Receive $24.5 Mln Milestone Payment From Sanofi For Recent TZIELD Approval

Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses

2026-06-23T10:15:09.000Z - 1 day ago

Sanofi Wins EU Approval For Cenrifki As First Disability-Targeting Therapy For SPMS Without Relapses

Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW

2026-06-23T09:07:51.000Z - 1 day ago

Sanofi Receives Marketing Rights For Wayrilz In Immune Thrombocytopenia From Japan's MHLW

EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis

2026-06-23T06:12:00.000Z - 1 day ago

EU Approves Sanofi's Cenrifki For Non-Relapsing Secondary Progressive Multiple Sclerosis

Sanofi Multiple Sclerosis Drug Gets EU Approval

Tue, 23 Jun 2026 01:37:00 -0400 - 1 day ago

Sanofi Multiple Sclerosis Drug Gets EU Approval

Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

2026-06-23T05:22:00.000Z - 1 day ago

Sanofi: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Tue, 23 Jun 2026 01:15:00 -0400 - 1 day ago

Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia

Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

2026-06-23T05:10:00.000Z - 1 day ago

Sanofi: Sanofi's Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation

2026-06-22T23:36:00.000Z - 1 day ago

The Department of Health - Abu Dhabi: DoH and Sanofi Partner to Advance Vaccine Innovation

Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics

2026-06-22T22:26:39.000Z - 1 day ago

Sanofi (SNY) Drives $24.5M Milestone Payment to MacroGenics

MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

2026-06-22T20:48:00.000Z - 2 days ago

MacroGenics, Inc.: MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

MacroGenics to receive $24.5M milestone payment from Sanofi

2026-06-22T20:45:10.000Z - 2 days ago

MacroGenics to receive $24.5M milestone payment from Sanofi

MGNX

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

2026-06-22T20:43:00.000Z - 2 days ago

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD Approval

Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations

2026-06-22T14:56:56.000Z - 2 days ago

Sanofi (SNY) Appoints New R&D Chief Amidst Mixed Expectations

Sanofi appoints Paulo Fontoura as Global Head of R&D

2026-06-22T13:30:14.000Z - 2 days ago

Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi investors likely to view new R&D head as a positive, says BofA

2026-06-22T13:26:54.000Z - 2 days ago

Sanofi investors likely to view new R&D head as a positive, says BofA

Japan's MHLW Approves Sanofi's Subcutaneous Sarclisa For Multiple Myeloma

2026-06-22T09:43:55.000Z - 2 days ago

Japan's MHLW Approves Sanofi's Subcutaneous Sarclisa For Multiple Myeloma

Sanofi: Sanofi appoints Paulo Fontoura as Global Head of R&D

2026-06-22T06:10:00.000Z - 2 days ago

Sanofi: Sanofi appoints Paulo Fontoura as Global Head of R&D

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Mon, 22 Jun 2026 02:00:00 -0400 - 2 days ago

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi's Sarclisa Subcutaneous Combination Therapy Gets Japan Approval For Multiple Myeloma

2026-06-19T12:02:51.000Z - 5 days ago

Sanofi's Sarclisa Subcutaneous Combination Therapy Gets Japan Approval For Multiple Myeloma

Sanofi: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

2026-06-19T10:46:00.000Z - 5 days ago

Sanofi: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Fri, 19 Jun 2026 06:31:00 -0400 - 5 days ago

Press Release: Sanofi's Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100

2026-06-17T22:34:09.000Z - 6 days ago

Sanofi SA (SNY) Stock Down 3.5% -- Now Undervalued? GF Score: 73/100

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

2026-06-15T16:16:28.000Z - 9 days ago

Sanofi price target lowered to EUR 95 from EUR 100 at Deutsche Bank

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Mon, 15 Jun 2026 12:05:00 -0400 - 9 days ago

Sanofi: Information concerning the total number of voting rights and shares – May 2026

Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes

2026-06-13T15:55:51.000Z - 11 days ago

Sanofi (SNY) Gains FDA Approval for Expanded Use of Tzield in Type 1 Diabetes

FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes

2026-06-13T06:01:25.000Z - 11 days ago

FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes

Sanofi: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

2026-06-12T22:22:00.000Z - 11 days ago

Sanofi: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Fri, 12 Jun 2026 17:19:26 -0400 - 12 days ago

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Strong Buy Rating on Sanofi (SNY) Following Positive Study Results

2026-06-12T20:25:27.000Z - 12 days ago

Strong Buy Rating on Sanofi (SNY) Following Positive Study Results

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

Fri, 12 Jun 2026 08:22:00 -0400 - 12 days ago

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated

2026-06-10T15:31:27.000Z - 14 days ago

Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstated

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

2026-06-10T14:15:51.000Z - 14 days ago

Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

2026-06-10T13:40:33.000Z - 14 days ago

Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright

DNTH

Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics

2026-06-10T13:32:46.000Z - 14 days ago

Sanofi (SNY) Halts Phase 3 Study, Impacting Dianthus Therapeutics

Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt

2026-06-10T12:57:27.000Z - 14 days ago

Dianthus Therapeutics (DNTH) Shares Drop Over 20% Following Sanofi Trial Halt

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus

2026-06-10T11:42:17.000Z - 14 days ago

Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus

DNTH

Dianthus sinks after Sanofi halts CIDP Phase 3 study

2026-06-10T11:33:17.000Z - 14 days ago

Dianthus sinks after Sanofi halts CIDP Phase 3 study

DNTH

Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment

2026-06-10T11:26:19.000Z - 14 days ago

Sanofi (SNY) Halts Phase 3 Study on CIDP Treatment

Sanofi to halt riliprubart Mobilize phase 3 study

2026-06-10T10:17:00.000Z - 14 days ago

Sanofi to halt riliprubart Mobilize phase 3 study

Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns

2026-06-10T07:55:43.000Z - 14 days ago

Sanofi (SNY) Halts Phase 3 Trial of Riliprubart Due to Efficacy Concerns

Sanofi Discontinues Phase 3 MOBILIZE Trial For Riliprubart In Treating CIDP

2026-06-10T07:02:10.000Z - 14 days ago

Sanofi Discontinues Phase 3 MOBILIZE Trial For Riliprubart In Treating CIDP

Sanofi ends Phase 3 riliprubart trial after weak interim results

Wed, 10 Jun 2026 02:38:42 -0400 - 14 days ago

Sanofi ends Phase 3 riliprubart trial after weak interim results

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Wed, 10 Jun 2026 02:28:00 -0400 - 14 days ago

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

Sanofi: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

2026-06-10T05:10:00.000Z - 14 days ago

Sanofi: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Wed, 10 Jun 2026 01:00:00 -0400 - 14 days ago

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

2026-06-09T11:06:00.000Z - 15 days ago

Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector

2026-06-08T05:52:41.000Z - 16 days ago

Sanofi: EC Approves Sarclisa SC For Multiple Myeloma, First EU Therapy Via On-Body Injector

Sanofi: Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

2026-06-08T05:10:00.000Z - 16 days ago

Sanofi: Sanofi's Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Fri, 05 Jun 2026 07:00:00 -0400 - 19 days ago

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Press Release: Sanofi launches 2026 global employee stock purchase plan

Jun 4, 2026, 4:07 AM EDT - 20 days ago

Press Release: Sanofi launches 2026 global employee stock purchase plan

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 21 days ago

Sanofi Transcript: Jefferies Global Healthcare Conference 2026

Snowflake says Sanofi selects Snowflake Cortex AI for drug development

2026-06-02T14:30:23.000Z - 22 days ago

Snowflake says Sanofi selects Snowflake Cortex AI for drug development

SNOW

Sanofi announces FDA grants priority review to venglustat new drug application

2026-05-28T09:59:23.000Z - 27 days ago

Sanofi announces FDA grants priority review to venglustat new drug application

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

May 28, 2026, 1:00 AM EDT - 27 days ago

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi: Information concerning the total number of voting rights and shares - April 2026

May 19, 2026, 12:37 PM EDT - 5 weeks ago

Sanofi: Information concerning the total number of voting rights and shares - April 2026

Sanofi says rare lung disease drug outperforms standard care in trial

May 18, 2026, 3:36 PM EDT - 5 weeks ago

Sanofi says rare lung disease drug outperforms standard care in trial

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

May 18, 2026, 3:30 PM EDT - 5 weeks ago

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

May 6, 2026, 2:38 PM EDT - 7 weeks ago

Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

May 6, 2026, 12:42 PM EDT - 7 weeks ago

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Apr 29, 2026, 12:00 PM EDT - 2 months ago

Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Apr 24, 2026, 2:30 PM EDT - 2 months ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Apr 24, 2026, 6:09 AM EDT - 2 months ago

Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

Sanofi Earnings Call Transcript: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Earnings Call Transcript: Q1 2026

Sanofi Slides: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Slides: Q1 2026

Sanofi Earnings release: Q1 2026

Apr 23, 2026, 7:00 AM EDT - 2 months ago

Sanofi Earnings release: Q1 2026

Sanofi Posts Higher Sales Amid Leadership Transition

Apr 23, 2026, 2:08 AM EDT - 2 months ago

Sanofi Posts Higher Sales Amid Leadership Transition

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Apr 23, 2026, 1:35 AM EDT - 2 months ago

Sanofi's first quarter earnings edges past estimates ahead of CEO change

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

Apr 22, 2026, 5:30 PM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria

REGN

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Apr 22, 2026, 1:05 AM EDT - 2 months ago

Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Apr 22, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Apr 13, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

REGN

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Apr 7, 2026, 1:00 AM EDT - 2 months ago

Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Mar 31, 2026, 1:00 AM EDT - 3 months ago

Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

Mar 28, 2026, 11:00 AM EDT - 3 months ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

EU regulator backs Sanofi's injectable version of blood cancer drug

Mar 27, 2026, 9:36 AM EDT - 3 months ago

EU regulator backs Sanofi's injectable version of blood cancer drug

Press release: Availability of the Q1 2026 aide-mémoire

Mar 24, 2026, 2:30 AM EDT - 3 months ago

Press release: Availability of the Q1 2026 aide-mémoire

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Mar 24, 2026, 2:00 AM EDT - 3 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

REGN

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Mar 23, 2026, 7:57 AM EDT - 3 months ago

Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment

Sanofi launches innovation and operation centre in China

Mar 20, 2026, 10:58 AM EDT - 3 months ago

Sanofi launches innovation and operation centre in China

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 3 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Mirecule Expands Strategic FSHD Collaboration with Sanofi

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Mar 18, 2026, 2:00 AM EDT - 3 months ago

Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 3 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

ABBV AZN NVS

The Big 3: PR, ELF, SNY

Mar 17, 2026, 1:27 PM EDT - 3 months ago

The Big 3: PR, ELF, SNY

ELF PR

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Mar 12, 2026, 1:30 PM EDT - 3 months ago

Sanofi: Information concerning the total number of voting rights and shares - February 2026

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Mar 10, 2026, 4:16 PM EDT - 3 months ago

Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit

Press Release:  Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director

Mar 5, 2026, 3:16 AM EST - 3 months ago

Press Release:  Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director

Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report

Mar 4, 2026, 12:30 PM EST - 4 months ago

Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report

Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln

Mar 3, 2026, 6:13 PM EST - 4 months ago

Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln

Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Mar 2, 2026, 1:00 AM EST - 4 months ago

Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

Feb 27, 2026, 7:03 AM EST - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment

REGN

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Feb 27, 2026, 5:55 AM EST - 4 months ago

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

Feb 24, 2026, 9:30 AM EST - 4 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis

REGN

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Feb 19, 2026, 6:06 PM EST - 4 months ago

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions